Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients

doi:10.4292/wjgpt.v17.i2.114876

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

(29)

(26)

(0)

(472)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Pharmacol Ther. Jun 5, 2026; 17(2): 114876
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.114876

Table 1 Patient’s clinico-biological database, n (%)/median (interquartile range)

	Total (n = 213)	Chx+ (n = 103)	Chx- (n = 110)	P value
Sex male	107 (50.2)	31 (30.1)	76 (69.1)	< 0.001
Age (years)	51.66 ± 11.97	52.16 ± 10.97	51.51 ± 9.97	0.237
High blood pressure	102 (49.9)	54 (52.4)	48 (44)	0.139
Diabetes mellitus	104 (48.8)	41 (39.8)	63 (57.3)	0.008
Hypercholesterolemia	18 (8.5)	9 (8.7)	9 (8.2)	0.53
Hypertriglyceridemia	27 (12.7)	10 (9.7)	17 (15.5)	0.146
Metabolic syndrome	152 (71.4)	65 (63.1)	87 (79.1)	0.007
Weight (kg)	89.17 (54-136)	84.16 (54-123)	93.87 (56-136)	< 0.001
Size (cm)	169.28(150-190)	166.99 (154-190)	171.42 (150-188)	< 0.001
BMI (kg/m²)	31.06 (18.2-43.8)	30.16 (18.2-41.7)	31.9 (24.3-43.8)	0.002
Hip circumference (cm)	109.73 (78-140)	109.98 (78-140)	109.50 (80-136)	0.12
Waist size (cm)	108.65 (78-138)	107.62 (78-131)	109.62 (83- 138)	0.10
Chest perimeter (cm)	107.50 (80-128)	107.6 (80-126)	107.4 (80-128)	0.23
AST (UI/L)	29.95 (10.30-165.00)	29.47 (10.9-165)	30.40 (10.3- 89.0)	0.68
ALT (UI/L)	34.14 (7.0-161.0)	29.96 (7-161)	38.05 (9-117.65)	0.009
GGT (UI/L)	45.25 (8.9-299.3)	43.03 (8.9-299.3)	47.33 (12.46-211)	0.41
PAL (UI/L)	77.63 (21.13-370)	79.37(12-370)	76.00 (28.80-167)	0.44
prothrombin rate (%)	98.87 (80-100)	99.03(80-100)	98.71 (80-100)	0.53
Platelets (G mmol/L)	229.89 (89-502)	230.32(113-502)	229.50(89-470)	0.92
LDL Cholesterol (mmol/L)	2.95(0.67-5.89)	3.10(0.80-5.89)	2.81 (0.67-5.40)	0.02
HDL Cholesterol (mmol/L)	1.08 (0.21-4.10)	1.1(0.60-4.10)	1.07 (0.21-4.1)	0.72
Triglyceride (mmol/L)	1.82(0.58 15.24)	1.86(0.58-15.24)	1.79 (0.62-7.6)	0.70
HBA1c (%)	6.45 (4.2-10.35)	6.19(4.23-9.20)	6.69 (4.4-10.35)	0.001
Albumin (G/L)	44.42 (31.93-54.80)	44.42(33.02-54)	44.42(31.9-54.8)	0.99

Chx: Cholecystectomy; BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine amino transferase; GGT: Gamma glutamyl transferase; PAL: Phosphatase alkaline; LDL: Low density lipoprotein; HDL: High-density lipoprotein; HBA1c: Hemoglobin A1c.

Full Size Table

Citation: Amalou K, Belal N, Tibouk A, Ghedada Y, Rekab R, Fadel S, Debzi N, Bousloub A. Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients. World J Gastrointest Pharmacol Ther 2026; 17(2): 114876
URL: https://www.wjgnet.com/2150-5349/full/v17/i2/114876.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v17.i2.114876

Amalou K, Belal N, Tibouk A, Ghedada Y, Rekab R, Fadel S, Debzi N, Bousloub A. Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients. World J Gastrointest Pharmacol Ther 2026; 17(2): 114876 [PMID: 42273239 DOI: 10.4292/wjgpt.v17.i2.114876]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.